Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET
Company Participants
Werner Lanthaler - Chief Executive Officer
Laetitia Rouxel - Chief Financial Officer
Cord Dohrmann - Chief Scientific Officer
Craig Johnstone - Chief Operating Officer
Matthias Evers - Chief Business Officer
Conference Call Participants
Kirsty Ross-Stewart - Citi
Charles Weston - RBC Capital Markets
Pippa Pritchard - Morgan Stanley
Michael Ryskin - Bank of America
Steven Mah - TD Cowen
Werner Lanthaler
Welcome to our -- good morning. Good afternoon. Welcome to our Q3 Call. Resilient into the Future of Biopharma R&D. That’s how we titled this presentation, which we have uploaded to the Internet and you are welcome to join this call also with the presentation.
Resilience is all about being able to overcome the unexpected. Our goal of resilience is to follow science and technology and thrive together with our partners. So you will see throughout this presentation, that resilience is not what happens to you. Resilience for us is, how react -- how you react to something, how you will respond to something and how you recover from what happens to you.
I am here together with my team, which you see on slide number three of this presentation with Laetitia, with Matthias, with Craig and with Cord, and I want to thank them very much for driving resilience into our company stronger than ever before.
If you go to page number five of your presentation, you see the highlights and I want to stress basically only highlights on our Q3. And if we reflect a little bit on this year, you see that we are growing strong again with the cyberattack in the rear mirror now.
And when I say we grow strong again, reporting double digit growth of 14% on topline and 13% on bottomline, despite the cyberattack is a great result. More importantly, we are driving this company into the long-term future and here just a few events that highlight that.
For example, a major collaboration in neurodegeneration together with BMS was started in 2023. For example, the continued validation of our Just-Evotec Biologics business, where we have an excellent pipeline building moment that we witnessed altogether here.
The tech alliance with Sandoz, also an agreement with the Department of Defense, highlight this and make our second J.POD that we are building in Toulouse, an absolutely vital investment into the future.